GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Accelerate Diagnostics Inc (STU:1A80) » Definitions » 5-Year EBITDA Growth Rate

Accelerate Diagnostics (STU:1A80) 5-Year EBITDA Growth Rate : 33.10% (As of Dec. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Accelerate Diagnostics 5-Year EBITDA Growth Rate?

Accelerate Diagnostics's EBITDA per Share for the three months ended in Dec. 2024 was €-0.17.

During the past 3 years, the average EBITDA Per Share Growth Rate was 47.00% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 33.10% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 11.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Accelerate Diagnostics was 53.50% per year. The lowest was -263.80% per year. And the median was -6.50% per year.

Competitive Comparison of Accelerate Diagnostics's 5-Year EBITDA Growth Rate

For the Medical Devices subindustry, Accelerate Diagnostics's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Accelerate Diagnostics's 5-Year EBITDA Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Accelerate Diagnostics's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Accelerate Diagnostics's 5-Year EBITDA Growth Rate falls into.


;
;

Accelerate Diagnostics 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Accelerate Diagnostics  (STU:1A80) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Accelerate Diagnostics 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Accelerate Diagnostics's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Accelerate Diagnostics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Accelerate Diagnostics Inc (STU:1A80) » Definitions » 5-Year EBITDA Growth Rate
Comparable Companies
IINN TRIB VVOS IRIX LFWD ALUR ADGM QTIH BSGM RMSL ABT BSX SYK MDT XTER:SHL EW SZSE:300760 DXCM XAMS:PHIA ZBH
Traded in Other Exchanges
AXDX:USA AXDX:Mexico 0H8E:UK 1A80:Germany
Address
3950 South Country Club Road, Suite 470, Tucson, AZ, USA, 85714
Website
https://www.acceleratediagnostics.com
Accelerate Diagnostics Inc is an in vitro diagnostics company dedicated to providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. Its Clinical Microbiology products include Accelerate Pheno system, Accelerate PhenoTest BC Kit, and Accelerate Arc module & BC kit. The company earns the majority of its revenue from the domestic market. The group operates as one operating segment, deriving instrument, consumable, and service revenues from customers engaged in healthcare diagnostics within the United States. Product revenue is derived from the sale or rental of instruments and sales of related consumable products. Service revenue is derived from the sale of extended service agreements.

Accelerate Diagnostics Headlines

No Headlines